BMS-564929

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C14H12ClN3O3
Molecular Weight	305.716
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12[C@H](O)CCN1C(=O)N(C2=O)C3=C(C)C(Cl)=C(C=C3)C#N

InChI

InChIKey=KEJORAMIZFOODM-PWSUYJOCSA-N

InChI=1S/C14H12ClN3O3/c1-7-9(3-2-8(6-16)11(7)15)18-13(20)12-10(19)4-5-17(12)14(18)21/h2-3,10,12,19H,4-5H2,1H3/t10-,12+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C14H12ClN3O3
Molecular Weight	305.716
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17008401
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18270691 |

BMS-564929 is an investigational selective androgen receptor modulator, which is being developed by Bristol-Myers Squibb for treatment of the symptoms of age-related decline in androgen levels in men ("andropause"). Bristol-Myers Squibb presented data for BMS 564929 that showed favorable pharmacokinetics and the potential for use at a very low dose (0.03mg).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Androgen Receptor 167 Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17008401	Agonist 2678		2.11 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Andropause 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17008401	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats.	2007 Jan	17008401
Determination of benzimidazole- and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC-MS/MS.	2008 May	18270691

Patents

Sample Use Guides

In Vivo Use Guide

Sprague Dawley rats (42–56 d old, 200–250 g) were dosed once daily by oral gavage with BMS-564929 (0.00001–10 mg/kg) in solution/suspension of 80% PEG 400 and 20% Tween 20 for 14 d.

Route of Administration: Oral

In Vitro Use Guide

The human cancer epithelial breast cell lines MDA MB-453 and T47D, were used for radioligand competition binding assays. Binding assays were conducted by incubating BMS-564929 at various concentrations with either [3H]DHT or [3H]progesterone with the cells for 2 h at room temperature. BMS-564929 is a high affinity ligand for AR with a Ki of 2.11 ± 0.16 nm

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:41:22 GMT 2023` Edited by `admin` on `Fri Dec 15 15:41:22 GMT 2023`
Record UNII	9BLW27W4X7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BMS-564929

Common Name

English

BENZONITRILE, 2-CHLORO-3-METHYL-4-((7R,7AS)-TETRAHYDRO-7-HYDROXY-1,3-DIOXO-1H-PYRROLO(1,2-C)IMIDAZOL-2(3H)-YL)-

Systematic Name

English

Classification Tree Code System Code

WIKIPEDIA

Designer-drugs-BMS-564929